Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 Nov;40(6):367–375. doi: 10.1007/BF01525387

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies

Peter Ragnhammar 1, Jan Fagerberg 1, Jan-Erik Frödin 1, Peter Wersäll 1, Lars-Olof Hansson 2, Hakan Mellstedt 1,✉
PMCID: PMC11037713  PMID: 7627993

Abstract

A group of 86 patients with advanced colorectal carcinoma were treated with the mouse (m) (IgG2A) or chimeric (c) monoclonal antibody (mAb) 17-1A. Prior to therapy, no patient had detectable levels of antibodies to mAb17-1A. All mmAb17-1A-treated patients (n=76) developed antibodies against both idiotypic and isotypic determinants. Addition of granulocyte/macrophage-colony-stimulating factor (GM-CSF) to mmAb17-1A significantly enhanced the induction of anti-idiotypic (ab2) as well as anti-isotypic antibodies. Of the mmAb17-1A-treated patients, 16 developed type I allergic reactions. These patients had significantly higher concentrations of anti-(mouse Ig) antibodies than patients without type I reactions. Of these 16 patients, 5 had received mmAb17-1A alone; they constituted 9% of this group (5/56). The remaining 11 patients had been given mmAb17-1A together with GM-CSF, and represented 55% of this treatment group (11/20). The difference was statistically significant (P<0.001). Of 10 patients, 9 (90%) treated with cmAb17-1A and GM-CSF developed ab2. The ab2 concentration in this patient group was significantly lower compared to those treated with mmAb-17A. Anti-(mouse Ig) antibodies caused clinical symptoms requiring therapeutic intervention in fewer than 10% of the patients treated with mmAb17-1A alone. With the addition of GM-CSF, the antibody concentration as well as the frequency of allergic side-effects calling for medical action increased significantly. Significantly more patients with a high ab2 concentration (at least 15μg/ml) 1 month after completion of mAb therapy responded to mAb treatment as compared to those with a low ab2 concentration (P<0.05). Moreover, patients with a high ab2 concentration (at least 15 μg/ml) had a median survival time of 15 months while those with a lower concentration survived for a median time of 9 months (P=0.01).

Key words: Monoclonal antibodies, HAMA, Anti-idiotypic antibodies, GM-CSF, Colorectal carcinoma

References

  • 1.Adams DO, Hall T, Steplewski Z, Koprowski H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2A isotype containing increased numbers of macrophages activated for distinctive form of antibody dependent cytolysis. Proc Natl Acad Sci USA. 1984;81:3506. doi: 10.1073/pnas.81.11.3506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Baker TS, Begent RHJ, Dewji MR, Conlan J, Secher DS. Characterization of the antibody response in patients undergoing radioimmunotherapy with chimeric B72.3. Antibody Immunoconjugates Radiopharm. 1991;4:799. [Google Scholar]
  • 3.Balaszczyk-Thurin M, Thurin J, Hindsgaul O, Karlsson KA, Steplewski Z, Koprowski H. Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem. 1987;262:372. [PubMed] [Google Scholar]
  • 4.Cheung N-K, Cheung IY, Canete A, Yeh SJ, Kushner B, Bonilla MA, Heller G, Larson SM. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res. 1994;54:2228. [PubMed] [Google Scholar]
  • 5.Douillard JY, Lehur PA, Vignoud J, Blottiere H, Maurel C, Thedrez P, Kremer M, Le Mevel B. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. Hybridoma. 1986;5:139. [PubMed] [Google Scholar]
  • 6.Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumor necrosis factor α (CA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125. doi: 10.1016/s0140-6736(94)90632-7. [DOI] [PubMed] [Google Scholar]
  • 7.Epenetos AA, Kosmas C. Monoclonal antibodies for imaging and therapy. Br J Cancer. 1989;59:152. doi: 10.1038/bjc.1989.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Fagerberg J, Frödin J-E, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother. 1994;38:149. doi: 10.1007/BF01525635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Frödin J-E, Harmenberg U, Biberfeld P, Christensson B, Lefvert A-K, Rieger Å, Shetye J, Wahren B, Mellstedt H. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinoma. Hybridoma. 1988;7:309. doi: 10.1089/hyb.1988.7.309. [DOI] [PubMed] [Google Scholar]
  • 10.Frödin J-E, Faxas M-E, Hagström B, Lefvert A-K, Masucci G, Nilsson B, Steinitz M, Unger P, Mellstedt H. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome—an important antitumoral effector function? Hybridoma. 1991;10:421. doi: 10.1089/hyb.1991.10.421. [DOI] [PubMed] [Google Scholar]
  • 11.Herlyn DM, Koprowski H. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer. 1981;27:769. doi: 10.1002/ijc.2910270607. [DOI] [PubMed] [Google Scholar]
  • 12.Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen detection by means of monoclonal antibodies. Proc Natl Acad Sci USA. 1979;76:1438. doi: 10.1073/pnas.76.3.1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Herlyn D, Lubeck M, Sears H, Koprowski H. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods. 1985;85:27. doi: 10.1016/0022-1759(85)90271-6. [DOI] [PubMed] [Google Scholar]
  • 14.Herlyn D, Sears H, Iliopoulos D, Lubeck M, Douillard J-Y, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowski H. Anit-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma. 1986;5:51. [PubMed] [Google Scholar]
  • 15.Jerne NK. Towards a network theory of the immune system. Ann Immunol. 1974;125:373. [PubMed] [Google Scholar]
  • 16.Khazaeli MB, Saleh MN, Liu T, Kaladas PM, Gilman SC, LoBuglio AF. Frequent anti-V-regions immune response to mouse B72.3 monoclonal antibody. J Clin Immunol. 1992;12:116. doi: 10.1007/BF00918141. [DOI] [PubMed] [Google Scholar]
  • 17.Khazaeli MB, Conry RM, LoBuglio Human immune response to monoclonal antibodies. J Immunother. 1994;15:42. doi: 10.1097/00002371-199401000-00006. [DOI] [PubMed] [Google Scholar]
  • 18.Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patients? Proc Natl Acad Sci USA. 1984;81:216. doi: 10.1073/pnas.81.1.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol. 1973;124:171. [PubMed] [Google Scholar]
  • 20.LoBuglio AF, Saleh M, Peterson L, et al. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma. 1986;5:117. [PubMed] [Google Scholar]
  • 21.LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA. 1989;86:4220. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mellstedt H, Frödin J-E, Masucci G, Ragnhammar P, Fagerberg J, Hjelm A-L, Shetye J, Wersäll P, Österborg A. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol. 1991;18:462. [PubMed] [Google Scholar]
  • 23.Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol. 1987;139:1113–19. [PubMed] [Google Scholar]
  • 24.Ragnhammer P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H. Effect of the monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long lasting, complete remissions can be induced. Int J Cancer. 1993;53:751. doi: 10.1002/ijc.2910530508. [DOI] [PubMed] [Google Scholar]
  • 25.Reference deleted
  • 26.Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, the German Cancer Aid 17-1A Study Group Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 1994;343:1177. doi: 10.1016/s0140-6736(94)92398-1. [DOI] [PubMed] [Google Scholar]
  • 27.Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor; immunologically mediated and effector cell-independent effects. Cancer Res. 1987;47:3692. [PubMed] [Google Scholar]
  • 28.Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, Lee JY, Kazaeli MB. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data. Cancer Immunol Immunother. 1990;32:185. doi: 10.1007/BF01771455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sears HF, Herlyn D, Steplewski Z, Koprowski H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma. Hybridoma. 1986;5:109. [PubMed] [Google Scholar]
  • 30.Shaw D, Khazaeli MB, Suu L, Ghrayeb J, Daddona P, McKinney S, Lobuglio A. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol. 1987;138:4534. [PubMed] [Google Scholar]
  • 31.Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol. 1985;135:1530. [PubMed] [Google Scholar]
  • 32.Sindelar WF, Maher MM, Herlyn D, Sears HF, Steplewski Z, Koprowski H. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma. 1986;5:125. [PubMed] [Google Scholar]
  • 33.Sun L, Curtis P, Rabrowicz-Szulezyska E, Ghrayeb J, Morrison S, Chang N, Koprowski H. Chimeric antibodies with 17-1A derived variable and human constant regions. Hybridoma. 1986;5:17. [PubMed] [Google Scholar]
  • 34.Szala S, Froehlich M, Scollon M, Kasai Y, Steplewski Z, Koprowski H, Linnenbach AJ. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci USA. 1990;87:3542. doi: 10.1073/pnas.87.9.3542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin KM, Krummer PH. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science. 1989;245:301. doi: 10.1126/science.2787530. [DOI] [PubMed] [Google Scholar]
  • 36.Werier J, Cheung AH, Matas AJ. Anaphylactic hypersensitivity reaction after repeat OKT3 treatment. Lancet. 1991;337:1371. doi: 10.1016/0140-6736(91)93028-8. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES